Next-generation BTK inhibitors and their value in CLL

Anthony Mato

Anthony Mato, MD, MSCE, from the Hospital of the University of Pennsylvania, Philadelphia, PA, talks to us about next-generation BTK inhibitors such as acalabrutinib and their results in clinical trials, but notes that long-term follow-up is still required to assess their effectiveness. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video